Free Trial
NASDAQ:ABEO

Abeona Therapeutics (ABEO) Stock Price, News & Analysis

Abeona Therapeutics logo
$6.90 -0.21 (-2.95%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$6.88 -0.02 (-0.35%)
As of 08:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Abeona Therapeutics Stock (NASDAQ:ABEO)

Key Stats

Today's Range
$6.89
$7.15
50-Day Range
$5.57
$7.23
52-Week Range
$3.93
$7.54
Volume
596,792 shs
Average Volume
713,770 shs
Market Capitalization
$353.83 million
P/E Ratio
9.86
Dividend Yield
N/A
Price Target
$19.50
Consensus Rating
Buy

Company Overview

Abeona Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

ABEO MarketRank™: 

Abeona Therapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 135th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Abeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Abeona Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Abeona Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Abeona Therapeutics are expected to decrease in the coming year, from ($1.16) to ($1.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Abeona Therapeutics is 9.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.69.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Abeona Therapeutics is 9.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.80.

  • Price to Book Value per Share Ratio

    Abeona Therapeutics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Abeona Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    18.51% of the float of Abeona Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Abeona Therapeutics has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in Abeona Therapeutics has recently decreased by 0.71%, indicating that investor sentiment is improving.
  • Dividend Yield

    Abeona Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Abeona Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.51% of the float of Abeona Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Abeona Therapeutics has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in Abeona Therapeutics has recently decreased by 0.71%, indicating that investor sentiment is improving.
  • News Sentiment

    Abeona Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Abeona Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 3 people have searched for ABEO on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,417,827.00 in company stock.

  • Percentage Held by Insiders

    Only 6.90% of the stock of Abeona Therapeutics is held by insiders.

  • Percentage Held by Institutions

    80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Abeona Therapeutics' insider trading history.
Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABEO Stock News Headlines

HC Wainwright Has Negative Estimate for ABEO Q3 Earnings
Zacks Small Cap Issues Optimistic Estimate for ABEO Earnings
What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your IRA could be at risk. Here’s how to prepare.tc pixel
Q1 EPS Estimate for Abeona Therapeutics Reduced by Analyst
See More Headlines

ABEO Stock Analysis - Frequently Asked Questions

Abeona Therapeutics' stock was trading at $5.57 at the start of the year. Since then, ABEO stock has increased by 23.9% and is now trading at $6.90.

Abeona Therapeutics Inc. (NASDAQ:ABEO) announced its quarterly earnings data on Thursday, August, 14th. The biopharmaceutical company reported $1.71 EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $2.10. The biopharmaceutical company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $21.71 million.
Read the conference call transcript
.

Abeona Therapeutics shares reverse split before market open on Tuesday, July 5th 2022.The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Top institutional shareholders of Abeona Therapeutics include Adage Capital Partners GP L.L.C. (6.01%), Boone Capital Management LLC (2.45%), Geode Capital Management LLC (2.16%) and JPMorgan Chase & Co. (1.62%). Insiders that own company stock include Vishwas Seshadri, Joseph Walter Vazzano, Brendan M O'malley, Faith L Charles, Christine Berni Silverstein, Michael Amoroso, Leila Alland and Mark Alvino.
View institutional ownership trends
.

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), CymaBay Therapeutics (CBAY) and GE Aerospace (GE).

Company Calendar

Last Earnings
8/14/2025
Today
8/28/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABEO
Previous Symbol
OTCMKTS:ACCP
CIK
318306
Employees
90
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$18.00
Potential Upside/Downside
+182.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.70
Trailing P/E Ratio
9.86
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$63.73 million
Net Margins
N/A
Pretax Margin
18,188.50%
Return on Equity
89.05%
Return on Assets
45.64%

Debt

Debt-to-Equity Ratio
0.09
Current Ratio
6.73
Quick Ratio
6.65

Sales & Book Value

Annual Sales
$3.50 million
Price / Sales
101.09
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.19 per share
Price / Book
2.16

Miscellaneous

Outstanding Shares
51,280,000
Free Float
47,741,000
Market Cap
$353.83 million
Optionable
Optionable
Beta
1.55

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ABEO) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners